{
    "clinical_study": {
        "@rank": "51771", 
        "arm_group": {
            "arm_group_label": "Treatment (SBRT)", 
            "arm_group_type": "Experimental", 
            "description": "Patients undergo 5 fractions of prostate stereotactic body radiation therapy over 10-20 days with at least 40 hours between each fraction in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This clinical trial studies high-dose stereotactic body radiation therapy (SBRT) in treating\n      patients with low-, intermediate-, or high-risk localized prostate cancer. SBRT may be able\n      to send x-rays directly to the tumor and cause less damage to normal tissue"
        }, 
        "brief_title": "High-Dose Stereotactic Radiation for Prostate Cancer", 
        "condition": [
            "Adenocarcinoma of the Prostate", 
            "Recurrent Prostate Cancer", 
            "Stage I Prostate Cancer", 
            "Stage IIA Prostate Cancer", 
            "Stage IIB Prostate Cancer", 
            "Stage III Prostate Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Prostatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To assess treatment related gastrointestinal (GI) and genitourinary (GU) toxicity for\n      patients who undergo SBRT for localized prostate cancer.\n\n      SECONDARY OBJECTIVES:\n\n      I. Follow quality of life after SBRT using Expanded Prostate Cancer Index Composite (EPIC)\n      and American Urological Association (AUA) scores.\n\n      II. Assess biochemical control after high-dose SBRT.\n\n      OUTLINE:\n\n      Patients undergo 5 fractions of prostate stereotactic body radiation therapy over 10-12 days\n      with at least 40 hours between each fraction in the absence of disease progression or\n      unacceptable toxicity.\n\n      After completion of study treatment, patients are followed up at 1.5, 4, 8, and 12 months,\n      every 6 months for 4 years, and then annually thereafter."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The patient must have prostate adenocarcinoma proven by histologic diagnosis\n\n          -  The patient must have clinical stage T1a-T3b with localized prostate cancer\n             considered low, intermediate, or high risk as defined by the National Comprehensive\n             Cancer Network (NCCN) guidelines; any patient whom is defined as high-risk must\n             undergo screening with computed tomography (CT) or magnetic resonance imaging (MRI)\n             of the abdomen and pelvis as well as bone scan prior to enrollment for staging\n             purposes; low and intermediate risk patients do not require imaging for staging\n             unless they have a focal symptom warranting investigation\n\n          -  Performance status - Karnofsky performance status (PS) >= 70\n\n          -  Life expectancy of > 5 years, in the opinion of and as documented by the investigator\n\n          -  Patients must either already have fiducials already placed within the prostate, or\n             otherwise be candidates for prostate fiducial placement (no bleeding disorders which\n             may cause excessive bleeding with fiducial placement, INR < 2.0).\n\n          -  Patients must have prostate-specific antigen (PSA) drawn within the 90 days prior to\n             enrollment\n\n          -  Men must agree to use adequate contraception (double barrier method of birth control\n             or abstinence) for the duration of study participation and for 12 months after\n             completing treatment\n\n          -  Subjects must have the ability to understand and the willingness to sign a written\n             informed consent document\n\n        Exclusion Criteria:\n\n          -  Prior treatment toxicities must be resolved to =< grade 1 according to National\n             Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version\n             4.0\n\n          -  Patients who are receiving any other investigational agents\n\n          -  Evidence of metastatic disease prior to radiation\n\n          -  Patients with uncontrolled intercurrent illness including, but not limited to ongoing\n             or active infection, symptomatic congestive heart failure, unstable angina pectoris,\n             cardiac arrhythmia, or psychiatric illness/social situations that would limit\n             compliance with study requirements\n\n          -  Prior pelvic radiation therapy\n\n          -  Patients whom are planned to receive pelvic nodal radiation are excluded\n\n          -  Weight > 350 lbs\n\n          -  Contraindications to placement of fiducials required for high-precision image\n             guidance (e.g. bleeding disorders which may cause excessive bleeding with placement,\n             requirement for coumadin, international normalized ratio [INR] > 2.0)\n\n          -  Patients unable to maintain a full bladder during treatment\n\n          -  Previous prostatectomy\n\n          -  Inflammatory bowel disease\n\n          -  AUA score > 15 in spite of optimal therapy"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "38", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01664130", 
            "org_study_id": "CASE1812", 
            "secondary_id": "NCI-2012-01252"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (SBRT)", 
                "description": "Undergo SBRT", 
                "intervention_name": "stereotactic body radiation therapy", 
                "intervention_type": "Radiation", 
                "other_name": [
                    "SBRT", 
                    "stereotactic radiation therapy", 
                    "stereotactic radiotherapy"
                ]
            }, 
            {
                "arm_group_label": "Treatment (SBRT)", 
                "description": "Ancillary studies", 
                "intervention_name": "quality-of-life assessment", 
                "intervention_type": "Procedure", 
                "other_name": "quality of life assessment"
            }, 
            {
                "arm_group_label": "Treatment (SBRT)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 3, 2014", 
        "location": {
            "contact": {
                "email": "stephak@ccf.org", 
                "last_name": "Kevin L. Stephans", 
                "phone": "216-445-8285"
            }, 
            "facility": {
                "address": {
                    "city": "Cleveland", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "44195"
                }, 
                "name": "Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center"
            }, 
            "investigator": {
                "last_name": "Kevin L. Stephans", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "High-Dose Stereotactic Body Radiation Therapy in Treating Patients With Low-, Intermediate-, or High-Risk Localized Prostate Cancer", 
        "overall_official": {
            "affiliation": "Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center", 
            "last_name": "Kevin Stephans", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Excessive GI and GU toxicity will be defined as a grade 3 GU toxicity rate of \u226515%.", 
                "measure": "Number of patients with treatment related GI and GU toxicity as assessed by the NCI CTCTAE version 4.0", 
                "safety_issue": "Yes", 
                "time_frame": "1.5 months"
            }, 
            {
                "measure": "Number of patients with treatment related GI and GU toxicity as assessed by the NCI CTCTAE version 4.0", 
                "safety_issue": "Yes", 
                "time_frame": "4 months"
            }, 
            {
                "measure": "Number of patients with treatment related GI and GU toxicity as assessed by the NCI CTCTAE version 4.0", 
                "safety_issue": "Yes", 
                "time_frame": "8 months"
            }, 
            {
                "measure": "Number of patients with treatment related GI and GU toxicity as assessed by the NCI CTCTAE version 4.0", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01664130"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Quality of life as assessed by EPIC and AUA scores", 
                "safety_issue": "No", 
                "time_frame": "1.5 months"
            }, 
            {
                "measure": "Quality of life as assessed by EPIC and AUA scores", 
                "safety_issue": "No", 
                "time_frame": "4 months"
            }, 
            {
                "measure": "Quality of life as assessed by EPIC and AUA scores", 
                "safety_issue": "No", 
                "time_frame": "8 months"
            }, 
            {
                "measure": "Quality of life as assessed by EPIC and AUA scores", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Biochemical failure will be defined as a rise in PSA of 2.0 ng/dl above the post-treatment nadir.", 
                "measure": "Change in Biochemical response as measured by serum PSA", 
                "safety_issue": "No", 
                "time_frame": "1.5 months"
            }, 
            {
                "description": "Biochemical failure will be defined as a rise in PSA of 2.0 ng/dl above the post-treatment nadir.", 
                "measure": "Change in Biochemical response as measured by serum PSA", 
                "safety_issue": "No", 
                "time_frame": "4 months"
            }, 
            {
                "description": "Biochemical failure will be defined as a rise in PSA of 2.0 ng/dl above the post-treatment nadir.", 
                "measure": "Change in Biochemical response as measured by serum PSA", 
                "safety_issue": "No", 
                "time_frame": "8 months"
            }, 
            {
                "description": "Biochemical failure will be defined as a rise in PSA of 2.0 ng/dl above the post-treatment nadir.", 
                "measure": "Change in Biochemical response as measured by serum PSA", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Case Comprehensive Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Case Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}